ITEAK-SuCoSQua joint research

[Aethan]

ITEAK-SuCoSQua announces the success of a new "artificial uterus"
The rotating President of the institution, Accoleia Romulius, authorizes the start of trials in human models after the success in animals



After years of research in different animals, the ITEAK-SuCoSQua has published its first conclusions on the "artificial uterus" that they are developing, and they are authorized to move on to tests with human computer models after the success obtained in tests with animal fetuses .

This artificial uterus, which aims to simulate the conditions of a maternal uterus so that a correct development of the fetus can be carried out, has borne fruit in trials with animals, allowing young cows, sheep, dogs, cats, rabbits and horses to develop normally and have been born without problems derived from it. The study has had to delay years waiting to observe the growth of the animals to determine any abnormality derived from these uteri, but the study concludes that there is no "significant difference" that puts the health of the young at birth at risk, that at the moment they are "healthy, strong individuals who lead a normal life together with the rest of their species." Likewise, there are no neuronal or mental problems derived from the process.

In accordance with this, the rotating Presidency of the institution, which currently corresponds to the Grand Master of SuCoSQua Accoleia Romulius, has proceeded to authorize trials on computers for humans, and if conclusive results are obtained, move on to clinical trials.

These artificial uteri, controversial for some due to the "substitution of the maternal figure", would present a very simple mechanism, by creating an environment similar to amniotic fluid and a structure similar to the placenta, in addition to linking the fetus by means of tubes that they would fulfill the functions of the umbilical cord, thanks to their connection at the other end to machines that would be in charge of supplying the necessary nutrients. The tubes would have a series of macroscopic and microscopic filters to stop possible impurities and microorganisms that could affect the fetus, and it should be carried out in a fully sterilized environment to avoid any possible infection.

"This is a great day for us"

said Dr. Romulius

"and it will be even more so if we achieve promising results in the computer simulations, so that in the not so distant future we can provide a way for those couples who cannot have children due to the mother's uterine problems, or because spontaneous abortions or premature births occur, we have a much safer, closer, and more welcoming environment to provide to the future individual, in such a way that we save suffering and pain for many families ".

The biggest problems expected now in the development of this project in humans come from the need for the maternal contribution in providing certain components to the fetus, which scientists hope to be able to solve using molecular magnification techniques.

[Aethan]

ITEAK-SuCoSQua announces being in "the last stages" of having a vaccine against HIV
If its effectiveness is confirmed, Selucia and Kirlawa would become the first nations with this virus eradicated
June 4913


Selucian virologist and lead investigator Saturio Pantensus, rotating President of the institution

Virologist Saturio Pantensus said this afternoon, in a paper published in several prestigious scientific journals, that the vaccine against HIV is "closer" than ever. According to the publicly available article, the vaccine is in the final stages of testing, with human individuals, and preliminary results are expected within two to three years. From then on, if the results are positive enough, the last phase of the vaccine would begin: its production.

The vaccine, which induces an immune response against HIV (known as "active vaccination approach") in opposition to "pasive vaccination approach" (which consists of preformed antibodies against HIV); it would therefore be a preventive vaccine, which would prevent infection with the virus, and therefore would put an end to the need for current therapeutic treatments. This vaccine would be made of an adenovirus (medium-sized, nonenveloped viruses with an icosahedral nucleocapsid containing a double stranded DNA genome commonly used for gene therapy and vaccinations) vector vaccine engineered to be effective against multiple strains of HIV found accross Terra, and a protein vaccine.

Well known to the general public but commonly mistaken with its illness (AIDS, Acquired ImmunoDeficiency Syndrome), HIV viruses or Human Immunodeficiency Viruses are two species of Retrovirus, whose illness causes progressive failure in our immune system that allows other opportunistic infections and to thrive in the organism. It is a sexually transmitted infection that can happen by contact with human fluids or transfer of blood, but it is untransmittable if the patient presents an undetectable viral load.

When the amount of CD4+ T cell decline below what is known as a critical level, cell-mediated immunity is lost and the body increasingly becomes more susceptible to opportunistic infections, which is the phase we know the development of AIDS.

During the study for the effectiveness of this vaccine, patients will receive intramuscularly six injections within one year, and that was effective during its phase in animals. This phase will be divided in two: four doses of the vaccine will come from a vaccine candidate that uses an engineered common-cold virus that does not cause illness (known as adenovirus serotype 26, or Ad26) and two vaccinations will be given together with a bivalent (two-component) HIV envelope protein formulation, combining envelope proteins, adjuvanted by aluminum phosphate to boost immune responses.

"We have high hopes for this vaccine,"

said Mr. Pantensus, who lost his own son as a result of this disease.

"This is a joint achievement by all of our nation's scientists, and one more example of what we, as human beings, could achieve if we all rowed in the same direction."

At the moment, the rest of the details of the investigation remain hidden to avoid leaks or plagiarism.

Candidates who so wish may present themselves as study subjects by filling out the application below.
______________________________________________________________________________________________________________

Some of the information published in this post comes from the actual research that is being carried out, with studies on a future phase III HIV vaccine: https://www.nih.gov/news-events/news-re ... cas-europe